Ledger.Open graph →
SEC Form D · filed January 21, 2021

Xilio Therapeutics, Inc

Offering
$50.2M
Sold
$50.2M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
WALTHAM, MA
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (33)

Rene Russo · Waltham, MAExec · DirectorMichael Ross · Waltham, MADirectorDavid Grayzel · Waltham, MADirectorJoseph Farmer · Waltham, MAExecDaniel Curran · Waltham, MADirectorPaul Clancy · Waltham, MADirectorRachel Humphrey · Waltham, MADirectorDaniel Lynch · Waltham, MADirectorTimothy Clackson · Waltham, MAExecPeter Dudek · Waltham, MADirectorSrini A. Surendranath · Powell, OHExecMatthew Butcher · Longmont, CODirectorDaniel A. Charna · Powell, OHExec · DirectorJeff Feinstein · SEATTLE, WADirectorRiyaz Nooruddin · GRAND CAYMAN, Cayman IslandsDirectorMatthew A. Jones · Powell, OHDirectorSheri C. Jones · Powell, OHExecLeo Backer · SEATTLE, WADirectorIvana Faltysova · GRAND CAYMAN, Cayman IslandsDirectorNancy Hong · Waltham, MADirectorRobert Weisskoff · Saddle Brook, NJDirectorJeffrey Williams · Dallas, TXDirectorCarl Sparks · Dallas, TXDirectorScale Venture Capital Management Group LLC · Dover, DEDirectorJoshua Owen · Raleigh, NCDirectorEvan Edwards · Raleigh, NCExecKevin Mosley · Raleigh, NCExec · DirectorJeffrey Williams · Raleigh, NCExecSerge De Reus · Amsterdam, P7DirectorPriyanka Chopra · San Francisco, CADirectorPeter Dudek · Waltham, MADirectorNancy Hong · Waltham, MADirectorRobert Weisskoff · Berkeley, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗

Xilio Therapeutics, Inc. — SEC Form D filing (2021) | Ledger